AMP drug
Evidence from:
primary |
all sources
Related entities (10)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| age | regulates | AMP | — | 1 |
| AMP | risk_factor_for | ADHD | — | 1 |
| AMP | risk_factor_for | aggression | — | 1 |
| AMP | regulates | AMPK | — | 1 |
| AMP | risk_factor_for | learning disabilities | — | 1 |
| AMPK | interacts_with | AMP | — | 1 |
| caloric restriction | regulates | AMP | — | 1 |
| education | regulates | AMP | — | 1 |
| race/ethnicity | regulates | AMP | — | 1 |
| region of residence | regulates | AMP | — | 1 |
Mentioned in (7)
Papers in which this entity is mentioned.
- Chromosomal instability as a driver of cancer progression. (2025)
- ENPP1 Immunobiology as a Therapeutic Target. (2023)
- Alcohol metabolism and epigenetics changes. (2013)
- Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease. (2011)
- Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interaction. (2010)
- Neuroimaging of children following prenatal drug exposure. (2009)
- Neuroimaging of children following prenatal drug exposure. (2009)
Merged raw entities (1)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| amp | drug | 7 | 12 |